Table 1

Baseline characteristics (prior to pregnancy) for each diagnostic group

Diagnosis
Number included
MFS
N=100
BAV
N=49
TS
N=16
vEDS
N=4
TAD
N=20
Total
N=189
P value
Age (median (IQR))29.1 (25.4–32.8)31.1 (25.4–34.3)30.2 (27.6–34.3)2831.1 (28.5–36.5)31.5 (29–36.9)0.17
Nulliparity57/100 (57%)18/48 (38%)10/16 (63%)2/4 (50%)12/20 (60%)99/188 (53%)0.18
Arterial hypertension12/97 (12%)3/48 (6%)4/16 (25%)1/4 (25%)4/19 (21%)24/184 (13%)0.33
Smoking
(current-former)
4-10/761-6/360-3/151-0/40-0/136-19/1440.32
BMI (median (IQR))22 (20.4–24.7)25.3 (21.9–30.7)27.3 (24.3–30.8)22.4 (20–29.4)24.5 (22.2–26.5)24.5 (22.2–26.5)0.01
Emerging country19/100 (19%)18/49 (37%)0/160/43/20 (15%)40/189 (21%)0.01
Aortic dilatation41/59 (69%)24/42 (57%)1/16 (6%)0/315/20 (75%)81/140 (58%)<0.001
Dimension AA in mm (median (IQR))40 (35–45)42 (40–44.3)42 (42–42)/41.5 (39.3–46.8)42 (38–45)0.68
Prior aortic dissection5/100 (5%)0/420/161/4 (25%)5/20 (25%)11/182 (6%)<0.001
 A5510/11
 B11/11
 BB4/51/12/2
BAV4/96 (4%)491/16 (6%)0/4054/185 (29%)<0.001
Valvular intervention9/34 (26%)6/17 (35%)0/30/12/9 (22%)17/64 (27%)0.92
 Aortic4 (1M, 1B, 2?)6 (3M, 1B, 2R)//2 (2M)12 (6M, 2B, 2R, 2?)
 Mitral5 (1M, 1B, 3?)////5 (1M, 1B, 3?)
Treatment
 BB27/54 (50%)5/18 (28%)4/7 (57%)2/2 (100%)6/10 (60%)44/91 (48%)0.037
 ACE-I1/49 (0.02%)1/18 (0.06%)0/70/31/13 (0.08%)3/90 (0.03%)0.34
 ARB1/47 (0.02%)0/180/70/20/131/87 (0.01%)0.56
 Diuretics1/49 (0.02%)0/180/70/30/130/900.93
 VKA4/17 (24%)4/8 (50%)0/10/01/7 (14%)9/33 (15%)0.59
  • Categorical variables are presented as count divided by the total number of valid/available data and percentages between brackets.

  • ?, unknown; AA, ascending aorta; ACE-I, ACE inhibitor; ARB, angiotensin receptor blocking agent; B, bioprosthesis; BAV, bicuspid aortic valve; BB, beta-blocking agent; IQR, interquartile range; M, mechanical valve; MFS, Marfan syndrome; OAC, oral anticoagulation; R, valve repair; TAD, thoracic aortic aneurysms and dissections; vEDS, vascular Ehlers-Danlos syndrome; VKA, vitamin K antagonist.